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Late-onset Alzheimer’s disease (LOAD) is a multifactorial disease with the potential 
involvement of multiple genes. Complex diseases such as LOAD have a large affect on public 
health due to the significant financial burden of health care for these individuals. Genetics plays 
a significant role in the etiology of the disease, therefore it is of public health importance that the 
genetics of LOAD be investigated. There is a known association between APOE gene variants 
and LOAD. No additional genes have been consistently demonstrated to be associated with risk 
of LOAD. Multiple recent genome-wide association studies (GWAS) have found variants 
showing significant association with LOAD. Twelve SNPs were chosen from four GWAS for a 
replication study to determine if the associations seen between SNPs and AD risk in the 
respective studies were present in our population. Ten additional positional candidate SNPs were 
chosen on chromosome 10 because of observed linkage peaks for AD and predicted imprinted 
genes in this region. We genotyped these 22 SNPs as well the E2/E3/E4 APOE polymorphism in 
up to 993 Caucasian Americans with LOAD and up to 976 age-matched healthy Caucasian 
Americans. Our data showed no statistically significant associations between the 22 SNPs 
examined and the risk of AD. Stratification by APOE*4 carrier status also failed to reveal 
statistically significant associations. Additional analyses were performed to examine the 
potential associations between the 22 SNPs and age-at-onset, disease duration, and baseline 
MMSE score. The analysis revealed significant associations between two SNPs, rs3746319 
(p=0.002) and rs16934131 (p=0.045), and age-at-onset. One SNP, rs16934131 (p=0.0002), was 
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found to be significantly associated with disease duration. Three SNPs, rs16934131 (p=0.002), 
rs12781609 (p=0.012), and rs5984894 (p=0.009), were found to be associated with baseline 
MMSE score in controls. Of note, rs16934131, demonstrated statistically significant association 
with age-at-onset, disease duration, and MMSE score. Further study may be necessary to 
definitively rule out associations between these variants and LOAD. 
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1.0  BACKGROUND 
1.1 INTRODUCTION 
Alzheimer’s disease (AD) is the most common neurodegenerative disease and accounts 
for approximately two-thirds of individuals with dementia. AD can be classified by the age-at-
onset (AAO) and the presence or lack of family history. AD can be divided into early-onset 
(before 60 years of age) and late-onset (after 60 years of age). Sporadic AD is classified as a lack 
of significant family history of AD and familial AD is classified by a significant family history. 
Sporadic AD makes up approximately 90% of cases, while familial AD accounts for the 
remaining 10%. Three genes have been implicated in the etiology of early-onset AD: amyloid 
precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2).  These genes follow 
an autosomal dominant pattern of inheritance and represent approximately 50% of early-onset 
AD and less than 1% of all AD cases. Late-onset AD (LOAD) is a thought to be a multifactorial 
disease, and is therefore potentially affected by multiple genes and environmental factors. To 
date, the only known significant genetic risk factor for LOAD is apolipoprotein E (APOE) 
(Kamboh 2004). 
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1.2 EPIDEMIOLOGY OF ALZHEIMER’S DISEASE 
 In 2009, it was estimated that 5.3 million people in the United States had AD, of which 5.1 
million were age 65 or older (Alzheimer's Association  2009). Worldwide, about 35 million 
people are affected with AD (World Alzheimer Report  2009). The risk of AD increases with 
age, therefore the number of persons with AD is expected to grow as more individuals continue 
to live longer. Due to recent advances in medicine enabling more individuals to live into their 
80s and 90s, the burden of AD has dramatically increased over the past decades and continues to 
rise. In 2000, there were an estimated 411,000 new cases of AD in the United States and this 
number is expected to increase to 454,000 new cases in 2010. By 2050, the number of new cases 
of AD is projected to be 959,000 (Alzheimer's Association  2009). 
In 2009, the total annual cost of Alzheimer’s and other dementias in the United States 
was estimated to be 148 billion dollars. Individuals with AD and other dementias are high users 
of healthcare and long-term care services. This includes hospital stays due to disease-related 
injuries and complications, as well as adult day center services, assisted living, and nursing home 
care (Alzheimer's Association  2009). The average individual with AD requires 2.75 years of 
nursing home care, over 10 times the national median length of stay for all causes (Welch et al. 
1992). A prolonged period of institutionalization and the high expensive of long term care 
combine to make the costs of AD extensive. The great proportion of the financial burden in the 
elderly population and greater is placed on Medicare and/or Medicaid. In 2004, the total per-
person payments for health and long-term care were three times higher for Medicare 
beneficiaries over 65 years with AD than for other Medicare beneficiaries in the same age group 
(Alzheimer's Association  2009). The costliness of all medical services necessary to care for the 
ever-growing AD population add up to a tremendous financial burden. 
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1.3 PATHOGENESIS AND DIAGNOSIS 
There are two pathological features of AD: extracellular senile plaques and the presence of 
intracellular neurofibrillary tangles. These extracellular senile plaques are mainly made up of the 
42 amino acid amyloid β peptide (Aβ-42) that is derived from the amyloid precursor protein 
(APP). APP is a transmembrane protein that undergoes proteolytic cleavage by either α- or β-
secretase and subsequent cleavage by γ-secretase. When APP is cut by α-secretase and then by γ-
secretase, a harmless peptide is generated. Conversely, when APP is cut first by β-secretase and 
then by γ-secretase, it generates peptides that vary between 39-43 amino acids in length. Aβ-40 
is the most common and Aβ-42 accounts for approximately 10% of Aβ. Aβ-40 is considered 
harmless, while Aβ-42 is neurotoxic and involved in the formation of senile plaques in AD 
brains (see Kamboh 2004 and references therein).  
Microtubules are one of the main structural components of cells. Microtubules are made 
up of a protein called tubulin that polymerizes to form straight, thin structures that provide the 
cell with support, shape, and transportation for substances. The microtubule network is held 
together by tau, which helps provide stability to the cell.  In the brains of AD, 
hyperphosphorylation causes tau to self-aggregate, leading the microtubule assembly to collapse. 
The aggregated tau molecules form a twisted paired-helical filament-like structure, thus named 
tau neurofibrillary tangles (see Kamboh 2004 and references therein). 
A clinical diagnosis of AD can be made following a neurological exam that includes 
various cognitive parameters. These clinical features include loss of the ability to smell, 
progressive decline in memory and intellectual ability, deteriorating language and speech skills, 
loss of orientation and behavioral abilities (see Kamboh 2004 and references therein). Clinical 
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diagnoses can be classified as possible or probable. Probably AD is when the individual has no 
other illness that may be contributing to symptoms whereas possible AD is when the individual 
meets criteria for another illness that may contribute to cognitive delay (Vilalta-Franch et al. 
2010). A definitive diagnosis of AD can only be made based on post-mortem studies, specifically 
the presence of pathological hallmarks in the brain. 
One method for determining an individual’s degree of cognitive impairment and/or 
dementia is the mini-mental state examination (MMSE). The MMSE measures orientation to 
time and place, registration, attention and calculation, recall, language, repetition, and complex 
commands using various types of tests (Folstein et al. 1975).  
 
1.4 ENVIRONMENTAL RISK FACTORS FOR LOAD 
LOAD is considered a multifactorial condition in which several environmental and genetic risk 
factors contribute to the etiology of the disease. Consideration of environmental factors is a 
necessary part of studying potential genetic factors that may contribute to risk for LOAD. There 
are several hypothesized environmental risk factors for LOAD, including education level, 
gender, tobacco and alcohol use, head trauma, cerebrovascular disease, and cholesterol levels. 
Although there are many possible risk factors for LOAD, most of the data is questionable. The 
only proven risk factor for LOAD is age.  
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1.4.1 Education 
Several studies have investigated the effect of education level on AD risk. It has been proposed 
that a low level of education is a risk factor for LOAD. A study by Sando et al. (2008) found that 
education had a consistently protective influence on the risk of developing AD. They found that 
this effect was dose-dependent and was still evident after correcting for age, sex, and APOE*4 
status. Other studies found no dose-dependent effect, but rather a threshold effect, in which 
individuals who had reached a certain education level benefited from the protective effect 
(Letenneur et al. 1999). The dose-dependent finding by Sando et al. (2008) is important because 
it suggests that education is causatively protective against AD, rather than a representation of 
confounding factors.  
The mechanism behind the protective effect of education is debated. Pathological studies 
on brains of individuals with LOAD revealed no correlations between education level and 
amyloid deposition (Bennett et al. 2005). Therefore, it is hypothesized that higher level of 
education allows individuals to withstand the effect of amyloid deposition on cognitive function. 
Therefore, pathologically there is no difference between individuals with varying education 
levels, but the effect on cognition is changed. “Cognitive reserve” or “brain reserve” theory 
proposes that education provides a neurological “reserve” through changes in neurons or 
processing efficiency, which allows the clinical symptoms of neurodegeneration in AD to occur 
later. Therefore, people with higher levels of education show symptoms later than those with less 
education (Paradise et al. 2009). Individuals with higher education levels may be more prepared 
to cope with these pathological changes because their brain can use the pre-exisiting cognitive 
processing that was acquired throughout their lifetime, particularly during challenging tasks 
during education (Sando et al. 2008). Cognitive reserve theory also suggests that individuals with 
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higher levels of education will have shorter disease duration, as they are hypothetically farther in 
the pathological disease progression at time of their diagnosis. However, Paradise et al. (2009) 
found that there was no change in time of death after diagnosis based on education. Others 
theorize that the association between education level and AD risk is not causative, but rather 
represents a confounding factor. This confounding factor could be a genetic factor representing 
innate intelligence, which one would infer would lead to a propensity for higher levels of 
education. This same genetic factor could be responsible for protecting the individual from 
LOAD. Yet others argue that years of study do not accurately reflect innate intelligence because 
other factors, such as financial means, may prevent individuals from continuing with schooling. 
However, the correlation is still seen between higher education levels and lower LOAD risk, 
suggesting that education, not innate intelligence, is the true protective factor (Sando et al. 2008).  
It is important to note that other factors that influence education level may be 
confounding the data. Individuals who are less educated may have jobs that involve manual 
labor. These types of occupations may make them more likely to be exposed to toxic substances 
and head trauma (Letenneur et al. 1999). Additionally, because AD cannot be definitely 
diagnosed until autopsy, clinical diagnosis is based on the observation and reporting of 
appearance of symptoms. Lower or higher education levels may affect the time which symptoms 
are first reported. For example, it may be more difficult to detect symptoms of cognitive 
impairment in an individual with a lower education level. Alternately, symptoms may be more 
noticeable in individuals with higher education levels because they may have greater 
occupational demands (Mejia et al. 2003). All studies that investigate the effect of education on 
AD risk are at risk for participation bias.  
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1.4.2 Gender 
As there is a difference in LOAD prevalence between men and women, gender is thought to be a 
risk factor for developing LOAD. One study found incidence of AD to be higher in women than 
men in all age groups. The risk for dementia was increased by 3.1 in women as compared to men 
(Letenneur et al. 1999). However, in Letenneur et al.’s study, AD incidence in women was lower 
than in men before the age of 80 and higher in women than men after age 80, suggesting a 
difference in AAO. Letenneur et al. (1999) offer several possible explanations for the observed 
differences in AD risk between men and women. Hormonal differences may explain the delay in 
occurrence in women. Some studies have found a negative association between estrogen 
replacement therapy and risk for AD (Kawas et al. 1997). Genetic differences between men and 
women may also play a part in this observed difference in AD risk between men and women; 
possible genetic risk factors that may be present on the X chromosome or protective factors on 
the Y chromosome. While biological factors may account for these differences, it is important to 
consider confounders such as social differences between men and women. The most prominent 
cofounder in this category is education level. On average, men have higher levels of education 
compared to women, particularly in older generations. However, after adjusting for education 
level, Letenneur et al. (2000) found that the association between AD risk and gender remained 
statistically significant. Another difference between men and women that could confound the 
results is alcohol consumption. Moderate wine consumption has been linked to lower AD risk 
(Letenneur et al. 2004). Therefore it is important to consider that men consume more wine on 
average than women when assessing differences in AD risk.  After adjusting for wine 
consumption, Letenneur et al. (2004) found that the association between AD and sex remained 
unchanged. As with any study of this potential association, Letenneur et al. (2004) reported that 
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participation bias may have affected their results, as most refusals to participate were younger, 
more often women, and were on average less educated. 
1.4.3 Tobacco and Alcohol Usage 
Tobacco use has been proposed to have a protective effect against the development of AD. AD is 
associated with cholinergic system deficits, which is characterized by reduced levels of 
acetylcholine and nicotinic receptors. Nicotine increases the release of acetylcholine and the 
number of nicotine receptors, and improves information processing and attention. For this 
reason, the protective effect of tobacco against AD is biologically plausible. Furthermore, case-
control studies have shown that long-term smoking habits are associated with a lower risk of AD 
in a dose-dependent fashion. Conversely, prospective studies have found an increased risk of AD 
associated with tobacco use. However, after adjusting for education level and occupation, the 
association between tobacco use and AD risk was not significant (Letenneur et al. 2004).  
Alcohol consumption has also been proposed as having a protective effect against the 
development of AD. Several studies found that light to moderate alcohol consumption was 
associated with lower risk of developing AD. The PAQUID study was a prospective study that 
studied wine consumption specifically, as it was the only type of alcohol consumed daily by 
most of the subjects (Orgogozo et al. 1997). Subjects were labeled as non-drinkers, light drinkers 
(1-2 glasses of wine per day), moderate drinkers (3-4 glasses per day), and heavy drinkers (more 
than four glasses per day). The risk of AD was decreased among light to moderate drinkers when 
compared to non-drinkers. The odds ratios for light, moderate, and heavy drinkers were 0.55, 
0.28, and 0.48, respectively. These results remained unchanged when adjusted for many potential 
confounders including age, sex, education level, smoking status, and MMSE. These results were 
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also looked at when stratified by APOE*4 carriers and non-carriers and showed that a light to 
moderate consumption seems to reduce the risk of AD among the subjects who have a higher 
genetic risk of developing AD. The underlying biological explanation for the association 
between alcohol consumption and AD is still unknown. One theory proposes that alcohol acts 
through reduction of cardiovascular risk factors, either by inhibiting platelet aggregation or 
through alteration of the serum lipid profile. Another theory states that alcohol might have a 
direct effect on cognition through release of acetylcholine in the hippocampus, which would 
hypothetically facilitate learning and memory (Letenneur et al. 2004).  
1.4.4 Head Trauma 
The effect of head injury has been related to dementia and AD risk in several studies. A study by 
Plassman et al. (2000) examined the AD and dementia risk in individuals with documented 
traumatic brain injury (TBI). TBI was classified as severe (loss of consciousness or posttraumatic 
amnesia longer than 24 hours), moderate (loss of consciousness of posttraumatic amnesia 
between 30 minutes and 24 hours), or mild (brief loss of consciousness or posttraumatic amnesia 
less than 30 minutes). Hazard ratios (HR) were calculated for the severity of head injury and AD. 
Severe TBI was found to have a HR of 4.51 and moderate TBI had a HR of 2.32. Mild TBI was 
not found to increase AD risk (HR 0.76). The overall hazard ratio for TBI and AD was 2.0 
(Plassman et al. 2000). In 2008, the Institute of Medicine stated that there is sufficient evidence 
of association between moderate or severe TBI and dementia of the Alzheimer type and that 
there is limited evidence of an association between mild TBI, with or without loss of 
consciousness, and dementia (Kumar and Kinsella 2010).   
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Pathological features similar to those in AD have been demonstrated in brains that have 
suffered TBI. Studies of traumatized brains a few hours after injury have shown deposition of β-
amyloid protein. Moreover, cerebral Aβ deposition was described in both short and long term 
brain trauma survivors. Production of APP was also noticed to be increased after TBI 
(Szczygielski et al. 2005). While the underlying biological explanation for the association 
between TBI and AD is still unknown, similarities in pathological features suggest a possible 
molecular link.  
1.4.5 Vascular Disease 
Cerebrovascular disease refers to any disease in which the arteries in the brain or arteries 
connected to the brain are defective or blocked. Studies have suggested an association between 
AD and factors that predispose individuals to cerebrovascular disease. Events which restrict 
blood supply to the brain, such as stroke, have been associated with increasing an individual’s 
risk of AD up to three fold, likely due to increased stress on the brain caused by these events.  
Factors that predispose individuals to cerebrovascular disease include hypertension, atrial 
fibrillation, carotid thickening, aortic sclerosis, and diabetes (Kalaria 2003). 
1.4.6 Cholesterol Levels 
The brain is a cholesterol-rich organ that maintains cholesterol homeostasis separately from the 
rest of the body, due to the blood-brain barrier (Hartmann et al. 2007). Cholesterol levels in the 
brain are strictly regulated by local synthesis and elimination of cholesterol in the form of 24(S)-
hydroxycholesterol and lipoprotein carrier APOE. Lipids may play a role in APP processing, 
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which leads to production of the 42 amino acid amyloid β peptide (Aβ-42). The action of γ 
secretase takes place in the lipid membrane, therefore lipid environment of the membrane may 
play a role in enzyme activity and the development of Aβ and AD (Hartmann et al. 2007). 
Studies have demonstrated that cholesterol levels are associated with AD risk. One study 
of men 70-89 years of age showed that high serum cholesterol level was highly correlated with 
the prevalence of AD in the study population. Additionally, individuals who take HMG-CoA 
reductase inhibitors (commonly known as statins), which lower cholesterol levels, have been 
shown to have lower prevalence and mortality from AD. The exact role of cholesterol in AD 
pathogenesis is unknown, yet there is evidence that there is a dose-dependent relationship 
between the level of cholesterol and the average onset of AD (Reiss 2005). Additionally, an 
increase in cholesterol levels is a risk factor for cerebrovascular disease, which is also a possible 
risk factor for AD (Kalaria 2003). 
1.5 GENETIC SUSCEPTIBILITY 
1.5.1 Genetics of Early Onset Alzheimer’s Disease 
Although AD is most commonly seen in the population age 65 and older, AD accounts for 30% 
of all nontraumatic dementia in individuals 30-64 years of age (Filley et al. 2007). The three 
genes known to be associated with early onset AD (EOAD) are PSEN1, PSEN2, and APP. These 
genes code for presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) 
(Ertekin-Taner 2007). Mutations in these genes typically follow an autosomal dominant pattern 
of inheritance. Approximately 30-50% of autosomal dominant familial AD cases have 
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identifiable mutations in one of these three genes (Filley et al. 2007).  Mutations in these three 
genes are thought to account for 50% of all EOAD cases (Kamboh 2004).  
APP is located in chromosome 21q21.2, PSEN1 at 14q24.3, and PSEN2 at 1q41 (Ertekin-
Taner 2007). Many mutations have been identified and reported in these genes. As of March 
2010, 178 mutations in PSEN1, 14 mutations in PSEN2, and 39 mutations in APP have been 
reported (http://www.molgen.ua.ac.be/Admutations 2010). 
The gene products of PSEN1 and PSEN2 are both present in brain tissue. PSEN1 and 
PSEN2 are part of the presenilin family, the members of which are involved in various biological 
processes. Presenilin 1 and presenilin 2 gene products have structural similarities, which suggests 
that their physiological functions may overlap. It has been hypothesized that PSEN1 and PSEN2 
code for the active sites of the γ-secretase enzyme. Therefore, mutations in PSEN1 or PSEN2 
would directly influence APP processing, leading to an increased production of Aβ-42 
(Zekanowski et al. 2004). 
1.5.2 Genetics of Late Onset Alzheimer’s Disease 
The etiology of LOAD has been particularly difficult to research due to its complexity. LOAD is 
thought to be a multifactorial condition in which genes and environment play a role. Liddell et al. 
(2001) reported a predicted risk of developing AD in first degree relatives of probands with AD 
as having a 3 to 4-fold increased risk compared to the general population.  It is estimated that 
heritability of LOAD is between 58-79% (Gatz et al. 2006).  A study performed by Reynolds et 
al. (2006) on the heritability of the age of onset of cognitive dysfunction estimated that 
approximately 35% of variation was due to genetic factors and 65% was attributed to 
environmental factors.  
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To date, the only known significant genetic risk factor for LOAD is apolipoprotein E 
(APOE), located on chromosome 19q13 (Borgaonkar et al. 1993).  Variations at codons 112 and 
158 lead to three common alleles: APOE*2, APOE*3, and APOE*4. The APOE*2 allele seems 
to be protective against AD, while the APOE*4 allele significantly increases an individual’s risk. 
The APOE*4 allele has a frequency of approximately 14% in the U.S. population. The effect of 
APOE*4 on AD risk is dose-dependent. AD risks for APOE*4 carriers are estimated to be 5 to 
15 times greater than that of the general population, depending on whether the individual has one 
or two copies (Cupples et al. 2004). Additionally, APOE*4 carriers have an earlier age at onset 
of AD, which is also dose-dependent (Panza et al. 2004).   
APOE is known to be associated with coronary artery disease (CAD) and the 
development of atherosclerosis, which may contribute to the pathogenesis of AD, considering 
that vascular disease has been linked to AD. Additionally, APOE is believed to be active in the 
central and peripheral nervous systems. APOE is thought to play a role in the mobilization and 
redistribution of cholesterol and in repair, growth, and maintenance of myelin and neuronal 
membranes during development and injury. APOE occurs in excessive amounts and co-localizes 
with Aβ plaques in the brains of individuals with AD. APOE has also been shown to have a 
strong stimulatory role in the polymerization of Aβ into amyloid filaments in in vitro studies. 
One hypothesis of APOE’s role in the molecular etiology of AD is that the APOE*4 isoform 
binds better with Aβ than the APOE*3 isoform and that APOE*4 acts as a molecular chaperone 
that facilitates Aβ accumulation in plaques (Panza et al. 2004). 
Although APOE is the only confirmed risk factor for LOAD, not all cases carry an APOE 
risk allele, and APOE does not explain the entire heritability of LOAD (Ertekin-Taner 2007, 
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Kamboh 2004). For this reason, researchers continue to search for additional contributing genetic 
factors in LOAD.  
1.5.3 Genome Wide Association Studies 
SNP-based genome wide association studies (GWAS) examine the entire human genome for 
SNP association to specific diseases, rather than examining SNPs that are biological and/or 
positional candidates. Studies on multifactorial conditions, such as LOAD, can utilize SNP-based 
GWAS to look for possible genetic factors. Recently several GWAS have been carried out to 
identify additional genes for AD.  
A genome wide association study by Bertram et al. (2008) identified rs179943, 
rs2049161, rs3826656, and rs11159647 to be associated with AD risk. SNP rs17993 is located in 
the ataxin-1 gene (ATXN1), at 6p23. The ATXN1 gene product, ataxin-1 protein, has been 
demonstrated to be present in various brain regions and in nonneuronal tissue, such as heart, 
skeletal muscle, and liver.  ATXN1 contains a CAG repeat region which codes for a 
polyglutamine tract which appears to have no effect on protein transcription or translation 
(Servadio et al. 1995). One group demonstrated that the mutated (expanded CAG tract) form of 
the protein appears to be more resistant to degradation (Cummings et al. 1999). Studies have also 
suggested that the resistance to degredation may lead to accumulation of the mutant protein, 
noting that the pathologic hallmark of neurodegenerative disorders associated with expanded 
polyglutamine repeats is the accumulation of polyglutamine inclusions. SNP rs2049161 is 
located at 18p11.3, approximately 150 kb from the psuedogene glyceraldehyde-3-phosphate 
dehydrogenase-like 11 (GAPDHL11). This pseudogene bears resemblance to the glyceraldehyde-
3-phosphate dehydrogenase, which is an enzyme that functions as part of the glycolysis pathway. 
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Evidence has shown that GAPDH glycolytic function is impaired in Alzheimer’s disease despite 
unchanged gene expression (Mazzola and Sirover 2001). SNP rs3826656 is located in the 
myeloid differentiation antigen CD33 gene (CD33), which located between 19q13.3 and 
19q13.4. The CD33 gene product has been demonstrated to be expressed by human monocytes, 
promyelocytes, myeloid blasts, some acute undifferentiated leukemias, and occasionally by acute 
lymphoblastic leukemias (Peiper et al. 1988). SNP rs11159647 is located at 14q31, 
approximately 100kb from the hypothetical gene LOC100287804. 
A genome wide association study by Beecham et al. (2008) identified rs7893928, 
rs16934131, rs7894737, rs11244841, rs3746319, rs11610206 to be associated with AD risk. SNP 
rs7893928 is located at 10q11.21, approximately 175 kb from pseudogene ribosomal protein L9 
pseudogene 21 (RPL921).  SNP rs16934131 is located in the potassium channel, calcium-
activated, large conductance, subfamily M, alpha member 1 gene (KCNMA1), at 10q22.3. 
KCNMA1 has been suggested to be associated with innate immunity, cochlear hearing, vascular 
dysfunction, epilepsy, and mental retardation. Knockout mice have been engineered by targeted 
disruption of the KCNMA1 gene which showed obvious ataxia, moderate vascular dysfunction, 
and independent neurologic deficits, including cerebellar dysfunction in the form of abnormal 
eye-blink reflexes, abnormal motion, and deficiency in motor coordination (Sausbier et al. 2004). 
SNP rs7894737 is located in the SorCS receptor 3 gene (SORCS3), at 10q23.3. SORCS1 and 
SORCS2 were identified as orthologs of VPS10 domain-containing receptor genes in mice. 
SORCS3 was named for similarities to the first two genes, but its exact function remains 
unknown (Hampe et al. 2001, Hermey et al. 1999). SNP rs11244841 is located in a disintigrin 
and metalloproteinase domain 12 (ADAM12), which is located at 10q26.3. The function of 
ADAM12 remains largely unknown, however studies have shown that ADAM12 expression 
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increases during muscle regeneration in mice (Galliano et al. 2000). SNP rs3746319 is located in 
the zinc finger protein 224 gene (ZNF224), between 19q13.2 and 19qter. The ZNF224 gene has 
been shown to have wide expression that was highest in hematopoietic tissues and cell lines (Han 
et al. 1999). The ZNF224 gene product has been suggested to function as a repressor, inhibiting 
transcription of various genes, including Wilms tumor 1 (WT1) (Lee et al. 2002).  SNP 
rs11610206 is located in the family with sequence similarity 113, member B gene (FAM113B), 
at 12q13.  
A genome wide association study by Reiman et al. (2007) identified rs2373115 to be a 
modifier of AD risk in APOE4 carriers.  This SNP is located in the GRB-associated binding 
protein 2 gene (GAB2), between 11q13.4 and 11q13.5. GAB2 has been implicated in coupling 
cytoplasmic-nuclear signal transduction (Zhao et al. 1999). GAB2 is located in a region 
commonly amplified in human breast cancer, and is overexpressed in breast cancer cell lines and 
primary tumors (Bentires-Alj et al. 2006).  
A genome wide association study by Carrasquillo et al. (2009) identified rs5984894 to be 
associated with AD risk. SNP rs5984894 is located in the protocadherin 11, X-linked gene 
(PCDH11X), at Xq21.3. PCDH11X is paired with PCDH11Y in a human-specific X/Y gene pair 
located in the Xq21.2/Yp11.2 homology block. They are both members of a family of calcium-
dependent cell adhesion and recognition proteins and are particularly prevalent in the central 
nervous system (Yoshida and Sugano 1999).  
A recent GWAS by Harold et al. (2009) of over 16,000 individuals revealed significant 
associations between AD and SNPs at two loci, 5’ to the PICALM gene and the CLU gene (also 
known as APOJ). Additionally, a GWAS by Lambert et al. (2009) identified two loci, CLU and 
CR1, which appeared to be associated with AD. PICALM encodes the phosphatidylinositol-
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binding clathrin assembly protein at 11q14. CLU encodes for clusterin or apolipoprotein J at 
8p21-p12.  CR1 encodes the complement component receptor 1 at 1q32. Roles of CLU and CR1 
in the clearance of Aβ have been suggested in previous biological studies (Lambert et al. 2009). 
Our group has examined APOJ, CR1 and PICALM in a large case-control study comprised of 
2,707 individuals. No association was observed with CR1 SNPs, however, a trend of association 
was seen with PICALM and CLU SNPs (Kamboh et al. 2010).  
In this study, a total of 12 SNPs were chosen from studies performed by Bertram et al. 
(2008), Beecham et al. (2009), Reiman et al. (2007), and Carrasquillo et al. (2009) for a 
replication study to determine if the associations seen between SNPs and AD risk in the 
respective studies were present in our population. 
 
1.5.4 SNPs in Putative Imprinted Genes 
Positional candidate SNPs were chosen on chromosome 10 because of observed linkage peaks 
which indicate that these regions are segregating with risk for AD (Kamboh 2004). The parent of 
origin effect has been hypothesized to play a role in AD risk (Bassett et al. 2002). One of the 
major mechanisms of parent of origin is imprinting. One study by Luedi et al. (2007) predicted 
potential imprinted genes in the human genome. Out of the SNPs available through TaqMan 
assays, we chose 10 SNPs that would best cover the hypothesized imprinted genes within the 
linkage region of chromosome 10. 
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1.6 STUDY OBJECTIVES 
The objective of this thesis project is to try to replicate the associations between AD and SNPs 
found by Bertram et al. (2008), Beecham et al. (2009), Reiman et al. (2007), and Carrasquillo et 
al. (2009) and test for any possible associations between SNPs in putative imprinted genes on 
chromosome 10 and AD risk. Additionally, we will test if any of these SNPs have associations 
with age at onset (AAO), disease duration, and mini mental state examination (MMSE) score.  
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2.0  METHODS 
2.1 SUBJECTS 
2.1.1 Sample Population 
Subjects were 1,969 Caucasian American individuals, including 993 LOAD cases and 976 older 
controls. In the AD group, 67.1% were female and 8.3% were autopsy-confirmed. The mean 
age-at-onset in AD cases was 72.9 ± (SD) 6.3 years. In the control group, 60.2% were female 
and 1.2% were autopsy confirmed. The mean age of controls at baseline was 74.2 ± 6.2 years. 
The subjects were recruited with informed consent and the study was approved by the University 
of Pittsburgh Institutional Review Board 
DNA was isolated from blood using the QIAamp blood DNA Maxi kit protocol (Qiagen, 
Valencia, CA), and from brain tissue using the QIAamp DNA Mini kit protocol. A small number 
of samples with insufficient amounts of DNA were amplified using the GenomiPhi kit (GE 
Healthcare).  
2.2 GENOTYPE DETERMINATION 
Information on SNPs studied in this thesis project can be found in Table 1.  
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Table 1. Study SNPs 
dbSNP Chromosome Location Mapped ID 
Rationale for 
Examination 
rs179943 6p23 ATXN1 GWAS 
rs35011589 10p14 GATA3 Putative Imprinted Gene 
rs7893928 10q11.21 200kb 5’ of CXCL12 GWAS 
rs16934131 10q22.3 KCNMA1 Intron GWAS 
rs7894737 10q25.1 SORCS3 Intron GWAS 
rs11244841 10q26.3 ADAM12 Intron GWAS 
rs11542965 10q26.3 PAOX Putative Imprinted Gene 
rs1049951 10q26.3 PAOX Putative Imprinted Gene 
rs11101654 10q26.3 VENTX2 Putative Imprinted Gene 
rs11599284 10q26.3 VENTX2 Putative Imprinted Gene 
rs2270192 10q26.3 VENTX2 Putative Imprinted Gene 
rs2240891 10q26.3 VENTX2 Putative Imprinted Gene 
rs7907431 10q26.3 C10orf93 Putative Imprinted Gene 
rs4500406 10q26.3 C10orf93 Putative Imprinted Gene 
rs12781609 10q26.3 C10orf93 Putative Imprinted Gene 
rs2373115 11q14.1 GAB2 GWAS 
rs11610206 12q13 FAM113B GWAS 
rs11159647 14q31 100kb from LOC100287804 GWAS 
rs2049161 18p11.3 150kb 5’ of GAPDHL11 GWAS 
rs3746319 19q13.2 ZNF224 GWAS 
rs3826656 19q13.3 1.5 kb 5’ of CD33 GWAS 
rs5984894 Xq21.3 PCDH11X Intron GWAS 
 
2.2.1 TaqMan Assay 
The genotypes for 19 SNPs were determined using TaqMan SNP genotyping Assays (Applied 
Biosystems, Foster City, CA). The SNP number and assay identification numbers for each SNP 
are listed in Table 2. 
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Table 2. TaqMan SNP genotyping Assays 
dbSNP Chromosome Location Gene Assay ID 
Sequence 
[VIC/FAM] 
dbSNP 
alleles 
rs179943 6p23 ATXN1 C__10031092_10 A/G C/T 
rs35011589 10p14 GATA3 C__25760909_10 C/G C/G 
rs7893928 10q11.2 CXCL12 C__26949936_10 C/T C/T 
rs16934131 10q22.3 KCNMA1  C___2003447_10 C/T C/T 
rs7894737 10q25.1 SORCS3  C__11759269_10 A/C A/C 
rs11244841 10q26.3 ADAM12  C___1701036_10 C/T C/T 
rs11542965 10q26.3 PAOX C__61810215_10 C/T G/A 
rs1049951 10q26.3 PAOX C___7468389_10 G/A C/T 
rs11101654 10q26.3 VENTX2 C__31984593_10 A/C A/C 
rs11599284 10q26.3 VENTX2 C__31984728_10 A/G A/G 
rs2270192 10q26.3 VENTX2 C__27105356_10 A/G C/T 
rs2240891 10q26.3 VENTX2 C__15872002_10 G/A C/T 
rs7907431 10q26.3 C10orf93 C__29348997_10 T/C C/T 
rs4500406 10q26.3 C10orf93 C__27905453_10 G/C C/G 
rs12781609 10q26.3 C10orf93 C____204339_10 T/C C/T 
rs2049161 18p11.3 GAPDHL11 C__11499278_10 A/C A/C 
rs3746319 19q13.2 ZNF224  C__22274939_10 A/G C/T 
rs3826656 19q13.3 CD33 C___1487396_10 A/G A/G 
rs5984894 Xq21.3 PCDH11X  rs5984894_M T/C A/G 
 
 
 
The TaqMan analysis was performed on samples placed on 384-well plates. Each plate 
had a mixture of cases and controls, with ten percent of all samples repeated in order to assess 
error rate. Reaction components and cycling conditions were followed according to Applied 
BioSystems TaqMan protocol.   
The biochemical principle of TaqMan is briefly outlined as follows. The DNA is first 
amplified by utilizing the polymerase chain reaction (PCR) using specific probe-labeled primers, 
then the samples are read using the 7900HT Real-Time PCR system machine (Applied 
Biosystems). The samples are first placed on 384 well plates. A reaction mixture is then added to 
each sample which contains master mix, genotyping assay, and water. The genotyping assay 
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consists of sequence specific forward and reverse primers, one probe labeled at the 5’ end with 
VIC dye and one probe labeled at the 5’ end with FAM dye. A nonfluorescent quencher is 
attached to the 3’ end of each of these probes. The probes lie between the two primers and bind 
specifically to the SNP of interest.  
The 5’ VIC and FAM probes that are contained in the reaction mixture contain a 
“reporter” at one end and a “quencher” at the other end. When the reporter and quencher remain 
together, there is no fluorescence. Yet when they are separated, the reporter is no longer 
“quenched” and it fluoresces. These probes bind to the region containing the SNP of interest, 
each binding specifically to different alleles. AmpliTaq Gold® Polymerase with 5’ exo-nuclease 
activity is used in the PCR reaction. During the annealing process, the polymerase binds to the 
primers and begins elongation of the new DNA strand. As it proceeds along the DNA strand, the 
exo-nuclease activity of the polymerase removes any double-stranded DNA (dsDNA) that may 
be impeding its path. Therefore, when the polymerase reaches the attached probe during 
elongation, the 5’ exo-nuclease activity cleaves the probe. The probes that are cleaved allow for 
the VIC/FAM dye to separate from the quencher, which allows for the dye to fluoresce. The 
reaction is illustrated in Figure 1.  
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Figure 1. TaqMan Chemical Reaction 
The product is analyzed using the 7900HT Fast Real-Time PCR system. The 
fluorescence that is released by the probes is specific to VIC or FAM, and therefore each 
corresponding allele, and can be detected by the 7900HT Fast Real-Time PCR system machine. 
The fluorescence of each product is measured and placed on a graph accordingly. The output 
allows us to distinguish between the different clusters of fluorescence intesnsity that are seen for 
each genotype. An example of the results from a TaqMan analysis can be seen in Figure 2.  
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Figure 2.  Example Result from TaqMan Analysis 
2.2.2 Pyrosequencing 
Pyrosequencing™ (PSQ) was developed by Ronaghi et al. (1998) and is based on real time 
pyrophosphate (Ppi) detection, which is released as a result of nucleotide incorporation by DNA 
polymerase. Pyrosequencing can be used to determine sequences of short segments of DNA and 
therefore can be utilized in the genotype analysis of SNP.  
In short, 40 µL of binding buffer (10mM Tris-HCl pH 7.6, 2M NaCl, 1mM EDTA, 0.1% 
Tween20), 2µL Streptavidin Sepharose beads (Amersham Biosciences, Piscataway, NJ) and 18 
µL of high purity water were added to 20µL of the amplified biotinylated PCR product. This mix 
was then shaken for 10 minutes, which allowed binding of the biotinylated PCR DNA to the 
streptavidin beads. DNA molecules, now immobilized on the streptavidin beads, were next  
captured onto filter probes using a vacuum prep tool. The beads were then washed in 70% 
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ethanol for 10 seconds, denaturation solution (0.2M NaOH) for 10 seconds, and in a wash buffer 
(10mM Tris Acetate pH7.6) for 20 seconds. The purpose of these steps are to watch and denature 
the DNA so that the double stranded DNA (dsDNA) separates into its single stranded DNA 
(ssDNA) templates. Next, the suction was stopped and the ssDNA (on beads) were released into 
the wells of a PSQ 96 plate containing 9.5µL of annealing buffer and 0.5µL of sequencing 
primer in each well. This 96 well plate was next placed on a 90ºC heating block with heated lid 
for 2 minutes, followed by 2 minutes at room temperature. This heating process promotes 
annealing of the ssDNA with the sequencing primer. Analysis begins with the dispensation of the 
enzyme and substrate into each well of the plate. Essentially, DNA polymerase catalyzes 
synthesis of a DNA strand complimentary to the original sequence, which is coupled to a 
chemiluminescent reaction. This generates light proportional to the number of nucleotides 
incorporated into the elongating strand. The light is detected by a charge coupled device (CCD) 
camera that is located inside the PSQ system. PSQ software automatically analyzes the 
quantitative data and presents the data in the form of programs, which can easily be evaluated by 
the user. Examples of pyrograms for various genotypes can be seen in Figures 3 - 5. Figures 6 
and 7 show an outline view of Pyrosequencing™ assay and the general biochemical principles 
behind the Pyrosequencing™ reaction system.  
 
Figure 3. rs11610206 pyrogram example of TT genotype 
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Figure 4. rs11610206 pyrogram example of TC genotype 
 
 
Figure 5. rs11610206 pyrogram example of CC genotype 
 
 
Figure 6. An outline view of Pyrosequencing™ assay 
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Figure 7. The general principal behind Pyrosequencing™ assay (adapted from Ronaghi et al. 2001) 
 
The genotypes for three SNPs (rs2373115, rs11610206, and rs11159647) were 
determined by Pyrosequencing™ on the PSQ™ HS 96 system (Qiagen, Valencia, CA). Table 3 
contains the sequences of the primers used and the target sequence to analyze for each SNP 
genotyped by Pyrosequencing™. The Pyrosequencing™ analysis was performed on samples that 
were placed in 96 well plates. Approximately 10% of samples were repeated in order to assess 
error rate.  
Table 3. Primer sequences and sequences analyzed for SNPs genotyped by Pyrosequencing 
rs2373115 
GAB2 
Sequence to Analyze AG/TGCACTC 
Sequence Primer GACATGGATTTATAGTCCG 
Forward Primer AGACTTATGCGGACATGGATTT 
Reverse (biotinylated) Primer AGAAATGTTCGACCATCAATACTC 
rs11610206 
FAM113B 
Sequence to Analyze GCTAT/CTGC 
Sequence Primer GGTGATCTTTAGCCTCC 
Forward Primer GTTAATCTGCCTTGTGTCAATTTG 
Reverse (biotinylated) Primer ACTGGCACAATGGGCTAGGT 
rs11159647 
LOC10028 
7804 
Sequence to Analyze GCATG/AGTA 
Sequence Primer CATATAGCAAAGCTGCA 
Forward Primer GATGAGCTGGAGCCCATAAT 
Reverse (biotinylated) Primer AGGGCCCACACTAAGTACTCATCT 
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2.3 STATISTICAL METHODS 
Allele and genotype frequencies were calculated by the direct allele-counting method. Goodness 
of fit to Hardy-Weinberg Equilibrium was tested using X2 test. Differences between genotype 
and allele frequencies in cases and controls were tested with the X2 test. The X2 test was also 
used to test for differences between cases and controls, stratified by APOE*4 status and stratified 
by sex. These statistics were calculated using PLINK v1.07 (Purcell et al. 2007). 
Logistic regression was used to calculate odds ratios and confidence intervals, adjusted 
by age (in controls) or AAO (in cases) and APOE*4 status. Linear regression analysis was 
performed for AAO, disease duration (age at death – age at diagnosis), and baseline MMSE 
score. We used AAO and sex as covariates for disease duration, age at testing as a covariate for 
MMSE score, and APOE*4 status as a covariate for AAO. These calculations were done using 
PLINK v1.07 (Purcell et al. 2007).  
Kaplan-Meier analysis for AAO, in all subjects and stratified by APOE*4 status, and 
regression analysis for AAO were performed using R v2.7.2 (R Development Core Team 2007). 
Power was estimated using R v2.7.2 (R Development Core Team 2007).  
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3.0  RESULTS 
3.1 APOE POLYMORPHISM IN AD CASES AND CONTROLS 
APOE genotype frequencies are presented in Table 4. In cases, the 3/4 genotype was the most 
frequent genotype, representing 46% of the total case genotypes. The 3/3 genotype was the 
second most frequent, making up 38% of the total case genotypes. The remainder of the 
genotypes were below 10%. In controls, the 3/3 genotype was the most frequent, making up 65% 
of the total control genotypes. The remainder of the genotypes of controls were below 20%. 
While the frequency of the APOE*4 allele was significantly higher in cases than controls 
(p<0.001), the frequency of the APOE*2 allele was lower in cases than controls (p<0.001).  
 
Table 4. APOE polymorphism AD cases and controls 
 AD Cases Controls 
 n freq n freq 
3/3 394 0.384 654 0.653 
3/4 470 0.459 165 0.165 
2/3 39 0.038 141 0.141 
2/4 28 0.027 22 0.022 
4/4 92 0.090 14 0.014 
2/2 2 0.002 5 0.005 
Total (n) 1025  1001  
APOE*3 1297 0.633 1614 0.806 
APOE*4 682 0.333 215 0.107 
APOE*2 71 0.035 173 0.086 
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3.2 GENOTYPING ERROR RATE 
Of the 22 SNPs examined, the estimated error rate for rs2373115, rs11610206, 
rs11159647 (genotyped by Pyrosequencing) were 2.3%, 1.7%, and 3.3%, respectively. The 
genotyping error rate for all remaining SNPs using TaqMan was estimated to be <0.6%.  
3.3 MONOALLELIC SNPS 
Six of the 22 studied SNPs were found to be monoallelic when screened in up to 1978 
individuals. These SNPs include rs35011589, rs11542965, rs2270192, rs11101654, rs4500406, 
and rs7907431. These SNPs are excluded from subsequent tables and discussions. Additionally, 
one SNP, rs2240891, had minor allele frequency (MAF) of 0.002 in 1962 individuals. The minor 
allele frequency was identical in cases and controls, therefore this SNP is also excluded from 
subsequent tables and discussions. These seven SNPs were part of the putative imprinted genes 
on chromosome 10. We did not have prior knowledge about their being monoallelic. 
3.4 HARDY WEINBERG EQUILIBRIUM 
P-values based on Hardy Weinberg Equilibrium (HWE) analysis are listed in Table 5. All but 
one of the studied SNPs were found to be in HWE for both cases and controls. One SNP, 
rs2049161, was found to be out of HWE in the control population. However, when taking the 
number of tests performed into account, this is not statistically significant.  
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Table 5. p-values based on HWE for cases and controls 
SNP Gene p-value 
  cases controls 
rs179943   ATXN1 0.129 1.000 
rs7893928  CXCL12 0.803 0.061 
rs16934131   KCNMA1 0.399 0.617 
rs7894737   SORCS 0.947 0.501 
rs11244841   ADAM12 0.804 0.932 
rs1049951   PAOX 0.058 1.000 
rs11599284  VENTX2 0.670 0.341 
rs12781609   C10orf93 0.415 0.057 
rs2373115 GAB2 0.130 0.829 
rs11610206   FAM113B 0.123 1.000 
rs11159647   LOC100287804 0.394 0.550 
rs2049161   GAPDHL11 0.097 0.002 
rs3746319   ZNF224 0.915 0.526 
rs3826656  CD33 0.138 1.000 
rs5984894  PCDH11X 0.101 0.283 
 
 
3.5 DISTRIBUTION OF SNPS IN CASES AND CONTROLS 
Allele and genotype frequencies for 15 SNPs for cases and controls are given in Table 6. None of 
the SNPs revealed significant association with AD risk.   
 
 
Table 6. Distribution of SNPs in cases and controls 
SNP/Gene 
 
n Genotype Counts (frequency) p Allele frequency p 
   CC CT TT  C T  
rs179943 
ATXN1 
AD 907 784 (0.864) 115 (0.127) 8 (0.009) 0.192 0.928 0.072 0.177 
C 914 766 (0.838) 142 (0.155) 6 (0.007) 0.916 0.084  
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   CC CT TT  C T  
rs7893928 
CXCL12 
AD 989 716 (0.724) 250 (0.253) 23 (0.023) 0.523 0.850 0.150 0.854 
C 972 707 (0.727) 235 (0.242) 30 (0.031) 0.848 0.152  
   TT TC CC  T C  
rs16934131 
KCNMA1 
AD 993 563 (0.567) 363 (0.366) 67 (0.067) 0.494 0.750 0.250 0.518 
C 976 532 (0.545) 382 (0.391) 62 (0.064) 0.741 0.259  
   AA AC CC  A C  
rs7894737 
SORCS 
AD 979 353 (0.361) 469 (0.479) 157 (0.160) 0.724 0.600 0.400 0.500 
C 976 369 (0.378) 454 (0.465) 153 (0.157) 0.611 0.389  
   TT TC CC  T C  
rs11244841 
ADAM12 
AD 980 533 (0.544) 382 (0.390) 65 (0.066) 0.687 0.739 0.261 0.391 
C 965 543 (0.563) 363 (0.376) 59 (0.061) 0.751 0.249  
   AA AG GG  A G  
rs1049951 
PAOX 
AD 991 871 (0.879) 112 (0.113) 8 (0.008) 0.064 0.935 0.065 0.058 
C 971 875 (0.901) 94 (0.097) 2 (0.002) 0.950 0.050  
   GG GA AA  G A  
rs11599284 
VENTX2 
AD 992 755 (0.761) 219 (0.221) 18 (0.018) 0.382 0.872 0.129 0.100 
C 973 766 (0.787) 191 (0.196) 16 (0.016) 0.885 0.115  
   CC CT TT  C T  
rs12781609 
C10orf93 
AD 982 388 (0.395) 449 (0.457) 145 (0.148) 0.739 0.624 0.376 0.920 
C 974 391 (0.401) 430 (0.441) 153 (0.157) 0.622 0.378  
   GG GT TT  G T  
rs2373115 
GAB2 
AD 923 603 (0.653) 295 (0.320) 25 (0.027) 0.650 0.813 0.187 0.899 
C 915 601 (0.657) 283 (0.309) 31 (0.034) 0.812 0.189  
   TT TC CC  T C  
rs11610206 
FAM113B 
AD 957 793 (0.829) 152 (0.159) 12 (0.013) 0.554 0.908 0.092 0.853 
C 909 752 (0.827) 150 (0.165) 7 (0.008) 0.910 0.090  
   GG GA AA  G A  
rs11159647 
LOC100287804 
AD 942 270 (0.287) 481 (0.511) 191 (0.203) 0.560 0.542 0.458 0.774 
C 913 268 (0.294) 445 (0.487) 200 (0.219) 0.537 0.463  
   AA AC CC  A C  
rs2049161 
GAPDHL11 
AD 777 522 (0.672) 221 (0.284) 34 (0.044) 0.376 0.814 0.186 0.301 
C 840 589 (0.701) 213 (0.254) 38 (0.045) 0.828 0.172  
   GG GA AA  G A  
rs3746319 
ZNF224 
AD 980 655 (0.668) 292 (0.298) 33 (0.034) 0.858 0.817 0.183 0.705 
C 966 641 (0.664) 288 (0.298) 37 (0.038) 0.813 0.187  
   AA AG GG  A G  
rs3826656 
CD33 
AD 811 487 (0.600) 273 (0.337) 51 (0.063) 0.416 0.769 0.231 0.522 
C 875 504 (0.576) 321 (0.367) 50 (0.057) 0.759 0.241  
   GG GC CC  T C  
rs5984894 
PCDH11X 
 
AD 657 187 (0.285) 307 (0.467) 163 (0.248) 0.134 0.514 0.486 0.996 
C 588 147 (0.250) 308 (0.524) 133 (0.226) 0.514 0.486  
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3.6 POWER CALCULATION AT α = 0.05 FOR EXAMINED SNPS 
80% power at α = 0.05 to detect the effect of a SNP using an allele based test given the 
respective sample sizes on disease risk, are shown in Table 7. As indicated in the table, we had 
sufficient power to detect odds ratios greater than 1.2-1.59 and less than 0.68-0.83.  
 
Table 7. 80% power calculation at α = 0.05 for 15 SNPs 
SNP Gene n cases n controls 
> OR for 
risk allele 
< OR for 
protective allele 
rs179943 ATXN1 907 914 1.44 0.73 
rs7893928 CXCL12 989 972 1.31 0.78 
rs16934131 KCNMA1 993 976 1.24 0.81 
rs7894737 SORCS 979 976 1.21 0.83 
rs11244841 ADAM12 980 965 1.24 0.81 
rs1049951 PAOX 991 971 1.59 0.68 
rs11599284 VENTX2 992 973 1.36 0.76 
rs12781609 C10orf93 982 974 1.21 0.83 
rs2373115 GAB2 923 915 1.29 0.79 
rs11610206 FAM113B 957 909 1.43 0.73 
rs11159647 LOC100287804 942 913 1.21 0.83 
rs2049161 GAPDHL11 777 840 1.31 0.78 
rs3746319 ZNF224 980 966 1.28 0.79 
rs3826656 CD33 811 875 1.26 0.80 
rs5984894 PCDH11X 657 588 1.20 0.83 
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3.7 ADJUSTED ODDS RATIOS 
Age/AAO-, sex- and APOE*4-adjusted odds ratios and confidence intervals are given in Table 8. 
Odds ratios for covariates were similar across all SNPs. No statistically significant associations 
were found.  
Table 8. Odds ratios and confidence intervals for 15 SNPs , adjusted for age/AAO and APOE*4 status 
SNP Gene OR (95% CI) p-value 
rs179943 ATXN1 0.85 (0.65-1.10) 0.2218 
rs7893928 CXCL12 1.04 (0.86-1.26) 0.6620 
rs16934131 KCNMA1 0.89 (0.77-1.05) 0.1815 
rs7894737 SORCS 0.99 (0.87-1.15) 0.9615 
rs11244841 ADAM12 1.09 (0.93-1.28) 0.3016 
rs1049951 PAOX 1.32 (0.98-1.76) 0.0644 
rs11599284 VENTX2 1.07 (0.87-1.32) 0.5304 
rs12781609 C10orf93 1.01 (0.88-1.16) 0.8610 
rs2373115 GAB2 0.99 (0.83-1.20) 0.9900 
rs11610206 FAM113B 1.06 (0.83-1.35) 0.6264 
rs11159647 LOC100287804 0.99 (0.87-1.15) 0.9814 
rs2049161 GAPDHL11 1.11 (0.92-1.34) 0.2786 
rs3746319 ZNF224 0.94 (0.79-1.12) 0.4785 
rs3826656 CD33 0.90 (0.76-1.07) 0.2513 
rs5984894 PCDH11X 0.98 (0.84-1.14) 0.7945 
-  
3.8 STRATIFICATION BY APOE 
APOE stratified data for 15 SNPs are presented in Table 9. No statistically significant differences 
were found in genotype or allele frequencies between cases and controls, regardless of APOE*4 
status.   
 
 35 
Table 9. Distribution of 15 SNPs, based on APOE*4 carriers and non-APOE*4 carriers 
SNP/Gene    Genotype Count (allele frequency) p Allele frequency p 
   n CC CT TT  C T  
rs179943 
ATXN1 
No 
E4 
AD 393 341 (0.868) 47 (0.120) 5 (0.013) 
0.092 
0.927 0.073 
0.303 
C 730 610 (0.836) 116 (0.159) 4 (0.005) 0.915 0.085 
E4 
AD 514 443 (0.862) 68 (0.132) 3 (0.006) 
0.628 
0.928 0.072 
0.533 
C 183 155 (0.847) 26 (0.142) 2 (0.011) 0.918 0.082 
   n CC CT TT  C T  
rs7893928 
CXCL12 
No 
E4 
AD 417 297 (0.712) 110 (0.264) 10 (0.024) 
0.713 
0.844 0.156 
0.701 
C 772 547 (0.709) 200 (0.259) 25 (0.032) 0.838 0.162 
E4 
AD 572 419 (0.733) 140 (0.245) 13 (0.023) 
0.153 
0.855 0.145 
0.133 
C 192 153 (0.797) 34 (0.177) 5 (0.026) 0.885 0.115 
   n TT TC CC  C T  
rs16934131 
KCNMA1 
No 
E4 
AD 423 256 (0.605) 142 (0.336) 25 (0.059) 
0.184 
0.773 0.227 
0.095 
C 776 427 (0.550) 298 (0.384) 51 (0.066) 0.742 0.258 
E4 
AD 570 307 (0.539) 221 (0.388) 42 (0.074) 
0.637 
0.733 0.268 
0.941 
C 192 101 (0.526) 80 (0.417) 11 (0.057) 0.734 0.266 
   n AA AC CC  A C  
rs7894737 
SORCS 
No 
E4 
AD 413 149 (0.361) 206 (0.499) 58 (0.140) 
0.525 
0.610 0.390 
0.617 
C 775 301 (0.388) 360 (0.465) 114 (0.147) 0.621 0.379 
E4 
AD 566 204 (0.360) 263 (0.465) 99 (0.175) 
0.863 
0.593 0.407 
0.594 
C 194 67 (0.345) 90 (0.464) 37 (0.191) 0.577 0.423 
   n TT TC CC  T C  
rs11244841 
ADAM12 
No 
E4 
AD 412 220 (0.534) 167 (0.405) 25 (0.061) 
0.713 
0.737 0.263 
0.643 
C 764 424 (0.555) 291 (0.381) 49 (0.064) 0.745 0.255 
E4 
AD 568 313 (0.551) 215 (0.379) 40 (0.070) 
0.560 
0.740 0.260 
0.300 
C 193 113 (0.585) 70 (0.363) 10 (0.052) 0.767 0.233 
   n AA AG GG  A G  
rs1049951 
PAOX 
No 
E4 
AD 421 366 (0.869) 52 (0.124) 3 (0.007) 
0.151 
0.931 0.069 
0.061 
C 775 699 (0.902) 74 (0.095) 2 (0.003) 0.950 0.050 
E4 
AD 570 505 (0.886) 60 (0.105) 5 (0.009) 
0.013 
0.939 0.061 
0.463 
C 195 175 (0.897) 20 (0.103) 0 (0.000) 0.949 0.051 
   n GG GA AA  G A  
rs11599284 
VENTX2 
No 
E4 
AD 421 334 (0.793) 78 (0.185) 9 (0.021) 
0.881 
0.886 0.114 
0.969 
C 777 613 (0.789) 150 (0.193) 14 (0.018) 0.886 0.115 
E4 
AD 571 421 (0.737) 141 (0.247) 9 (0.016) 
0.322 
0.861 0.139 
0.231 
C 195 152 (0.779) 41 (0.210) 2 (0.010) 0.885 0.115 
   n CC CT TT  C T  
rs12781609 
C10orf93 
No 
E4 
AD 419 154 (0.368) 196 (0.468) 69 (0.165) 
0.501 
0.601 0.399 
0.292 
C 778 313 (0.402) 344 (0.442) 121 (0.156) 0.623 0.377 
E4 
AD 563 234 (0.416) 253 (0.449) 76 (0.135) 
0.618 
0.640 0.360 
0.416 
C 196 78 (0.398) 86 (0.439) 32 (0.163) 0.617 0.383 
   n GG GT TT  G T  
rs2373115 
GAB2 
No 
E4 
AD 383 242 (0.632) 127 (0.332) 14 (0.037) 
0.564 
0.798 0.202 
0.328 
C 729 484 (0.664) 220 (0.302) 25 (0.034) 0.815 0.185 
E4 
AD 540 361 (0.669) 168 (0.311) 11 (0.020) 
0.399 
0.824 0.176 
0.218 
C 178 111 (0.624) 61 (0.343) 6 (0.034) 0.795 0.205 
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   n TT TC CC  T C  
rs11610206 
FAM113B 
No 
E4 
AD 404 329 (0.814) 70 (0.173) 5 (0.012) 
0.635 
0.901 0.099 
0.656 
C 729 598 (0.820) 126 (0.173) 5 (0.007) 0.907 0.093 
E4 
AD 553 464 (0.839) 82 (0.148) 7 (0.013) 
0.752 
0.913 0.087 
0.733 
C 173 147 (0.850) 24 (0.139) 2 (0.012) 0.919 0.081 
   n GG GA AA  G A  
rs11159647 
LOC10028 
7804 
No 
E4 
AD 401 111 (0.277) 204 (0.509) 86 (0.214) 
0.842 
0.531 0.469 
0.755 
C 723 211 (0.292) 356 (0.492) 156 (0.216) 0.538 0.462 
E4 
AD 541 159 (0.294) 277 (0.512) 105 (0.194) 
0.333 
0.550 0.450 
0.457 
C 182 54 (0.297) 84 (0.462) 44 (0.242) 0.528 0.473 
   n AA AC CC  A C  
rs2049161 
GAPDHL11 
No 
E4 
AD 336 229 (0.682) 92 (0.274) 15 (0.045) 
0.964 
0.819 0.182 
0.779 
C 663 457 (0.689) 178 (0.268) 28 (0.042) 0.824 0.177 
E4 
AD 441 293 (0.664) 129 (0.293) 19 (0.043) 
0.054 
0.811 0.189 
0.172 
C 176 131 (0.744) 35 (0.199) 10 (0.057) 0.844 0.156 
   n GG GA AA  G A  
rs3746319 
ZNF224 
No 
E4 
AD 414 276 (0.667) 126 (0.304) 12 (0.029) 
0.900 
0.819 0.181 
0.941 
C 767 516 (0.673) 226 (0.295) 25 (0.033) 0.820 0.180 
E4 
AD 566 379 (0.670) 166 (0.293) 21 (0.037) 
0.299 
0.816 0.184 
0.200 
C 192 122 (0.635) 58 (0.302) 12 (0.063) 0.787 0.214 
   n AA AG GG  A G  
rs3826656 
CD33 
No 
E4 
AD 348 213 (0.612) 112 (0.322) 23 (0.066) 
0.452 
0.773 0.227 
0.865 
C 699 414 (0.592) 248 (0.355) 37 (0.053) 0.770 0.230 
E4 
AD 463 274 (0.592) 161 (0.348) 28 (0.060) 
0.166 
0.766 0.234 
0.073 
C 175 89 (0.509) 73 (0.417) 13 (0.074) 0.717 0.283 
   n TT TC CC  T C  
rs5984894 
PCDH11X 
No 
E4 
AD 279 79 (0.283) 138 (0.495) 62 (0.222) 
0.754 
0.529 0.471 
0.594 
C 465 120 (0.258) 239 (0.514) 106 (0.228) 0.516 0.484 
E4 
AD 378 108 (0.286) 169 (0.447) 101 (0.267) 
0.071 
0.503 0.497 
0.803 
C 116 26 (0.224) 66 (0.569) 24 (0.207) 0.511 0.489 
 
 
3.9 STRATIFICATION BY SEX 
Sex stratified data for 15 SNPs are presented in Table 10. One SNP, rs1049951/PAOX, 
showed a statistically significant difference between cases and controls in females (p=0.013). 
 
 
 37 
Table 10. Distribution of 15 SNPs, based on sex 
SNP/Gene   n Genotype count (frequency) p 
    CC CT TT  
rs179943 
ATXN1 
males AD 288 254 (0.882) 32 (0.111) 2 (0.007) 0.171 
 C 378 316 (0.836) 60 (0.159) 2 (0.005) 
females AD 619 530 (0.856) 83 (0.134) 6 (0.010) 0.628 
 C 536 450 (0.840) 82 (0.153) 4 (0.007) 
    CC CT TT  
rs7893928 
CXCL12 
males AD 323 239 (0.740) 77 (0.238) 7 (0.022) 0.867 
 C 385 278 (0.722) 98 (0.255) 9 (0.023) 
females AD 666 477 (0.716) 173 (0.260) 16 (0.024) 0.297 
 C 587 429 (0.731) 137 (0.233) 21 (0.036) 
    TT TC CC  
rs16934131 
KCNMA1 
males AD 324 174 (0.537) 126 (0.389) 24 (0.074) 0.888 
 C 387 214 (0.553) 147 (0.380) 26 (0.067) 
females AD 669 389 (0.581) 237 (0.354) 43 (0.064) 0.262 
 C 589 318 (0.540) 235 (0.399) 36 (0.061) 
    AA AC CC  
rs7894737 
SORCS 
males AD 322 111 (0.345) 155 (0.481) 56 (0.174) 0.215 
 C 389 159 (0.409) 168 (0.432) 62 (0.159) 
females AD 657 242 (0.368) 314 (0.478) 101 (0.154) 0.926 
 C 587 210 (0.358) 286 (0.487) 91 (0.155) 
    TT TC CC  
rs11244841 
ADAM12 
males AD 323 167 (0.517) 137 (0.424) 19 (0.059) 0.618 
 C 379 209 (0.551) 147 (0.388) 23 (0.061) 
females AD 657 366 (0.557) 245 (0.373) 46 (0.070) 0.798 
 C 586 334 (0.570) 216 (0.369) 36 (0.061) 
    AA AG GG  
rs1049951 
PAOX 
males AD 319 289 (0.906) 27 (0.085) 3 (0.009) 0.632 
 C 391 349 (0.893) 40 (0.102) 2 (0.005) 
females AD 672 582 (0.866) 85 (0.126) 5 (0.007) 0.013 
 C 580 526 (0.907) 54 (0.093) 0 (0.000) 
    GG GA AA  
rs11599284 
VENTX2 
males AD 321 251 (0.782) 64 (0.199) 6 (0.019) 0.957 
 C 391 308 (0.788) 75 (0.192) 8 (0.020) 
females AD 671 504 (0.751) 155 (0.231) 12 (0.018) 0.316 
 C 582 458 (0.787) 116 (0.199) 8 (0.014) 
    CC CT TT  
rs12781609 
C10orf93 
males AD 319 131 (0.411) 146 (0.458) 42 (0.132) 0.476 
 C 394 167 (0.424) 165 (0.419) 62 (0.157) 
females AD 663 257 (0.388) 303 (0.457) 103 (0.155) 0.997 
 C 580 224 (0.386) 265 (0.457) 91 (0.157) 
    GG GT TT  
rs2373115 
GAB2 
males AD 303 198 (0.653) 98 (0.323) 7 (0.023) 0.617 
 C 363 237 (0.653) 113 (0.311) 13 (0.036) 
females AD 620 405 (0.653) 197 (0.318) 18 (0.029) 0.892 
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*male genotype counts represent hemizygous individuals; p-value is that of allele based test  
 
3.10 LINEAR REGRESSION OF SNPS FOR AGE-AT-ONSET (AAO) 
Linear regression analysis was performed on APOE-adjusted AAO for each SNP. Results 
are show in Table 11. Linear regression analysis of APOE-adjusted AAO showed significant 
associations with rs16934131 in the KCNMA1 gene on 10q22.3 (p=0.045) and rs3746319 in 
 C 552 364 (0.659) 170 (0.308) 18 (0.033) 
    TT TC CC  
rs11610206 
FAM113B 
males AD 316 255 (0.807) 54 (0.171) 7 (0.022) 0.151 
 C 360 301 (0.836) 57 (0.158) 2 (0.006) 
females AD 641 538 (0.839) 98 (0.153) 5 (0.008) 0.713 
 C 549 451 (0.821) 93 (0.169) 5 (0.009) 
    GG GA AA  
rs11159647 
LOC10028 
7804 
males AD 303 77 (0.254) 163 (0.538) 63 (0.208) 0.056 
 C 368 119 (0.323) 165 (0.448) 84 (0.228) 
females AD 639 193 (0.302) 318 (0.498) 128 (0.200) 0.546 
 C 545 149 (0.273) 280 (0.514) 116 (0.213) 
    AA AC CC  
rs2049161 
GAPDHL11 
males AD 239 159 (0.665) 70 (0.293) 10 (0.042) 0.261 
 C 350 247 (0.706) 83 (0.237) 20 (0.057) 
females AD 538 363 (0.675) 151 (0.281) 24 (0.045) 0.666 
 C 490 342 (0.698) 130 (0.265) 18 (0.037) 
    GG GA AA  
rs3746319 
ZNF224 
males AD 318 204 (0.642) 101 (0.318) 13 (0.041) 0.704 
 C 382 251 (0.657) 112 (0.293) 19 (0.050) 
females AD 662 451 (0.681) 191 (0.289) 20 (0.030) 0.878 
 C 584 390 (0.668) 176 (0.301) 18 (0.031) 
    AA AG GG  
rs3826656 
CD33 
males AD 256 144 (0.563) 92 (0.359) 20 (0.078) 0.120 
 C 370 223 (0.603) 132 (0.357) 15 (0.041) 
females AD 555 343 (0.618) 181 (0.326) 31 (0.056) 0.121 
 C 505 281 (0.556) 189 (0.374) 35 (0.069) 
    TT TC CC  
rs5984894 
PCDH11X 
males* AD 320 159 (0.497) 0 (0.000) 161 (0.503) 0.522 
 C 378 197 (0.521) 0 (0.000) 181 (0.479) 
females AD 657 187 (0.285) 307 (0.467) 163 (0.248) 0.134 
 C 588 147 (0.250) 308 (0.524) 133 (0.226) 
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ZNF224 gene on 19q13.3 (p=0.002). APOE-adjusted mean average AAO for ZNF224/rs3746319 
genotypes GG, GA, and AA were 73.26 ± (SD) 5.9 (n=645), 72.08 ± 6.5 (n=288), and 71.15 ± 
6.1 (n=31) years, respectively. When using a recessive model, KCNMA1/rs16934131 had a p-
value of 0.007. APOE-adjusted mean average AAO for KCNMA1/rs16934131 genotypes TT + 
TC and CC were 73.0 ± (SD) 6.1 (n=912) and 70.9 ± 5.7 (n=65) years, respectively.  
Table 11.  Linear regression of SNPs for AAO, adjusted for APOE 
SNP Gene n p-value 
rs179943   ATXN1 897 0.860 
rs7893928  CXCL12 974 0.502 
rs16934131   KCNMA1 977 0.045 
rs7894737   SORCS 963 0.457 
rs11244841   ADAM12 965 0.509 
rs1049951   PAOX 980 0.539 
rs11599284  VENTX2 982 0.261 
rs12781609   C10orf93 971 0.931 
rs2373115 GAB2 908 0.645 
rs11610206   FAM113B 941 0.912 
rs11159647   LOC100287804 926 0.231 
rs2049161   GAPDHL11 766 0.631 
rs3746319   ZNF224 964 0.002 
rs3826656  CD33 800 0.170 
rs5984894  PCDH11X 961 0.833 
 
3.11 KAPLAN-MEIER ANALYSIS OF AGE AT ONSET 
Kaplan-Meier analysis was performed on AAO for two SNPs, KCNMA1/rs16934131 and 
ZNF224/rs3746319, on all subjects and stratified by APOE*4 carrier status. All p-values for 
Kaplan-Meier analysis can be found in Table 12. KCNMA1/rs16934131 was found to be 
statistically significant (p=0.002, n=993), particularly among non-APOE*4 carriers (p=0.001, 
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n=423). rs3746319 was found to be statistically significant among APOE*4 carriers (p=0.036, 
n=566). Kaplan-Meier plots for both SNPs are shown in Figure 8.  
 
Table 12. Kaplan-Meier analysis p-values of rs16934131 and rs3746319 
SNP  n p 
rs16934131 
KCNMA1 
 
all cases 993 0.002 
no E4 423 0.001 
E4 570 0.138 
rs3746319 
ZNF224 
all cases 980 0.165 
no E4 414 0.923 
E4 566 0.036 
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Figure 8. Kaplan-Meier analysis of rs16934131 and rs3746319 
 42 
3.12 REGRESSION ANALYSIS MODELING FOR INTERACTIONS OF SNPS IN 
AGE AT ONSET 
Regression analysis was performed on AAO for two SNPs, KCNMA1/rs16934131 and 
ZNF224/rs3746319.  Both SNPs were modeled as additive dominant or recessive, with or 
without interactions between APOE*4. The regression coefficients and p-values for the model 
with the best fit can be found in Table 13. 
Table 13. Regression coefficients and p-values for best-fit regression model 
Covariate Coefficient p-value 
APOE*4 -2.618 8.84 x 10-8 
rs16934131 (recessive) -3.411 0.008 
rs3746319 (additive) -0.285 0.613 
APOE*4 x rs16934131  2.422 0.138 
APOE*4 x  rs3746319 -1.294 0.079 
 
3.13 LINEAR REGRESSION OF SNPS FOR DISEASE DURATION 
Linear regression analysis was performed on AAO- and sex-adjusted disease duration for 
each SNP. Results are shown in Table 14.  Disease duration data was available on up to 86 AD 
cases. AAO and gender-adjusted disease duration showed significant association with 
KCNMA1/rs16934131 (p=0.0002) when using a dominant model. This SNP remained significant 
when taking the number of tests performed into account. Average disease duration for 
KCNMA1/rs16934131 genotypes TT and TC/CC, were 7.65 ± (SD) 3.6 (n=47) and 10.97 ± 3.98 
(n=35), respectively.  
 
 43 
Table 14.  Linear regression of SNPs for disease duration, adjusted for AAO and sex 
SNP Gene n p-value 
rs179943   ATXN1 80 0.361 
rs7893928  CXCL12 82 0.864 
rs16934131   KCNMA1 82 0.001 
rs7894737   SORCS 79 0.637 
rs11244841   ADAM12 83 0.074 
rs1049951   PAOX 84 0.804 
rs11599284  VENTX2 86 0.769 
rs12781609   C10orf93 84 0.656 
rs2373115 GAB2 73 0.892 
rs11610206   FAM113B 78 0.913 
rs11159647   LOC100287804 78 0.916 
rs2049161   GAPDHL11 65 0.198 
rs3746319   ZNF224 82 0.632 
rs3826656  CD33 67 0.203 
rs5984894  PCDH11X 80 0.709 
 
3.14 LINEAR REGRESSION OF SNPS FOR BASELINE MINI MENTAL STATE 
EXAM (MMSE) SCORE 
Linear regression analysis was performed on age- and sex-adjusted baseline MMSE score for 
each SNP. This analysis was performed on cases and controls separately. Results are shown in 
Table 14. Three SNPs, KCNMA1/rs16934131, C10orf93/rs12781609, and PCDH11X/rs5984894, 
showed statistically significant association with MMSE score in controls. The most statistically 
significant SNP was rs16934131 (p=0.002, n=896). Average MMSE score for 
KCNMA1/rs16934131 genotypes TT, TC, and CC were 28.52 ± (SD) 1.36 (n=484), 28.32 ± 1.42 
(n=355), and 27.96 ± 1.58 (n=57), respectively.  Average MMSE score for C10orf93/rs12781609 
genotypes CC, CT, and TT were 28.51 ± 1.40 (n=356), 28.36 ± 1.44 (n=393), 28.16 ± 1.44 
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(n=134), respectively. Average MMSE score for PCDH11X/rs5984894 genotypes TT, TC, and 
CC were 28.50 ± 1.40 (n=308), 28.50 ± 1.40 (n=296), 28.16 ± 1.45 (n=287), respectively.  
Table 15. Linear regression of MMSE, adjusted for age and sex 
SNP risk allele  n P 
rs179943 
ATXN1 
T AD 887 0.111 
C 824 0.628 
rs7893928 
CXCL12 
T AD 968 0.183 
C 889 0.345 
rs16934131 
KCNMA1 
C AD 971 0.502 
C 896 0.002 
rs7894737 
SORCS 
C AD 961 0.321 
C 893 0.987 
rs11244841 
ADAM12 
C AD 958 0.425 
C 886 0.487 
rs1049951 
PAOX 
G AD 970 0.990 
C 882 0.283 
rs11599284 
VENTX2 
A AD 971 0.362 
C 882 0.698 
rs12781609 
C10orf93 
T AD 962 0.170 
C 883 0.012 
rs2373115 
GAB2 
T AD 905 0.346 
C 834 0.758 
rs11610206 
FAM113B 
C AD 935 0.075 
C 828 0.937 
rs11159647 
LOC100287804 
A AD 922 0.190 
C 833 0.992 
rs2049161 
GAPDHL11 
C AD 760 0.345 
C 752 0.399 
rs3746319 
ZNF224 
A AD 959 0.891 
C 884 0.247 
rs3826656 
C33 
G AD 794 0.692 
C 788 0.070 
rs5984894 
PCDH11X 
C AD 956 0.456 
C 883 0.009 
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4.0  DISCUSSION 
LOAD is a multifactorial condition in which several environmental and genetic risk 
factors contribute to the etiology of the disease. There are several hypothesized environmental 
risk factors for LOAD, including education level, gender, tobacco and alcohol use, head trauma, 
cerebrovascular disease, and cholesterol levels. To date, the only known significant genetic risk 
factor for LOAD is APOE, of which there are three common alleles: APOE*2, APOE*3, and 
APOE*4. The APOE*2 allele seems to be protective against AD, while the APOE*4 allele 
significantly increases an individual’s risk. Although APOE is the only confirmed genetic risk 
factor for LOAD, not all cases carry an APOE risk allele, and APOE does not explain the entire 
heritability of LOAD (Kamboh 2004). Therefore, researchers continue to search for additional 
contributing genetic factors in LOAD.  
In order to identify the remaining genes for LOAD, efforts have been focused on a 
contemporary approach of GWAS, which is a hypothesis free approach and has the potential to 
identify all known and unknown genes. Recently, six GWAS have implicated additional genes 
for LOAD (Beecham et al. 2009, Bertram et al. 2008, Carrasquillo et al. 2009, Harold et al. 
2009, Lambert et al. 2009, Reiman et al. 2007). Since replication in independent studies is a gold 
standard before declaring an association being genuine, we have sought to replicate these 
associations in a large case-controls cohort. We have already replicated findings from two 
GWAS (Harold et al. 2009, Lambert et al. 2009) in our sample (Kamboh et al. 2010). The focus 
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of this study was to replicate 12 significant SNPs implicated in four GWAS (Beecham et al. 
2009, Bertram et al. 2008, Carrasquillo et al. 2009, Harold et al. 2009, Lambert et al. 2009, 
Reiman et al. 2007). We also screened 10 additional SNPs present in positional and biological 
candidate genes located on chromosome 10. In addition to disease risk, we also investigated the 
associations of these SNPs with AAO, disease duration, and MMSE score. 
We did not observe a statistically significant associations between the SNPs and the risk 
of AD in our primary analysis. Our data suggest that the association in the previously identified 
SNPs, if it exists, is not statistically significant in our study population. We were unable to 
replicate the reported GWAS signals in our large case-control samples. Additionally, the 
candidate SNPs from chromosome 10 also showed no association with AD risk. Furthermore, 
stratification by APOE*4 carrier status and stratification by sex failed to reveal any statistically 
significant associations between SNPs and AD risk.  
There are several possible explanations for failing to replicate the reported GWAS 
associations. One possible explanation is that there are differences between the populations used 
in the initial studies and the population used in our study. The findings of the various GWAS 
may in fact be reflecting environmental covariables present in the initial studies’ populations that 
were not present in our study population. Furthermore, heterogeneity in the sample populations 
may explain the discrepancies between our data and the results found by the various GWAS. The 
subjects used in this study were Caucasian, while Bertram et al.’s study population consisted of 
individuals who were of self-reported European ancestry and some individuals in their follow-up 
analyses were African American. The Carrasquillo et al. study included subjects that were of 
Caucasian and African American descent. The Beecham et al. study population consisted of 
individual’s of European descent. The term “Caucasian” refers to a large, heterogenous group of 
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individuals who may be descendants from various regions and countries. Therefore, while the 
populations used in our study and some of the original studies were primarily made up of 
Caucasian/European individuals, there could be substantial genetic heterogeneity between the 
subjects.  
Another possible explanation for the associations found by the original studies that were 
not replicated in our study could be the Winner’s Curse. The Winner’s Curse refers to a theory 
that in studies involving many tests, particularly in GWAS, the necessary high level of 
significance makes it likely that the first study to report a significant finding will also have an 
effect size much larger than is likely to be seen in replication studies. These “false positives”, 
will therefore not be replicated in subsequent studies, as these studies findings will tend to 
regress towards the mean (Nakaoka and Inoue 2009).  
While none of the SNPs examined in this study were found to be associated with AD 
risk, we observed some associations with AAO, disease duration, and MMSE score.   
Linear regression analysis of APOE-adjusted AAO showed significant associations with 
rs16934131 in the KCNMA1 gene on 10q22.3 (p=0.045) and rs3746319 in ZNF224 gene on 
19q13.3 (p=0.002). There was a gene-dosage effect of the ZNF224/rs3746319 SNP on AAO 
with the GG genotype with the highest value (73.26 years), the AA genotype with the lowest 
value (71.15 years) and the GA genotype with the intermediate value (72.08 years). Kaplan-
Meier analysis showed that the ZNF224/rs3746319 effect on AAO was mainly confined to 
APOE*4 carriers (p=0.036, n=566) as reflected by Figure 8 that shows obvious differences 
between the curve for the AA genotype as compared to those for the GA and GG. These data 
suggest that the A allele of ZNF224/rs3746319 is associated with earlier AAO.  
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For the KCNMA1/rs16934131 SNP, the CC genotype was associated with early AAO 
(70.88 years) than the TT and TC genotypes (73.00 years). Kaplan-Meier analysis of AAO 
showed that rs16934131 was found to be statistically significant (p=0.002, n=993), particularly 
among non-APOE*4 carriers (p=0.001, n=423). Kaplan-Meier plots seen in Figure 8 show 
obvious differences between the curve of the CC genotype as compared to those of the TT and 
TC genotypes, particularly in non-APOE*4 carriers. The fact that we are seeing a stronger effect 
of rs16934131 in non-APOE*4 carriers seems biologically plausible considering that APOE is 
known to have such a strong effect, it may mask other effects. These data suggest that the C 
allele of KCNMA1/rs16934131 is associated with earlier AAO.  
The differences between effects of these two SNPs when stratified by APOE*4 status is 
suggestive of interactions between these two genes and APOE. However, regression analysis did 
not reveal any statistically significant evidence for interactions between KCNMA1/rs16934131, 
ZNF224/rs3746319, and/or APOE. This may be partially explained by the fact that when running 
as many tests as is necessary in regression analysis, the power drops significantly.  
A study published by Li et al. (2002) identified potential linkage peaks for AD AAO on 
chromosome 10. One of these peaks was at 10q, which is also where KCNMA1/rs16934131 is 
located. Therefore, this gene may represent an actual risk factor or may be in linkage 
disequilibrium with a risk factor for AAO.  
The AAO of an individual with AD is dependent upon many factors. One of these factors 
is the method of diagnosis. As some individuals may have varying degrees of lucidity during 
their disease, a test of cognitive impairment may not detect all individuals at the exact onset of 
their disease. The diagnosis of AD is also partially depending on report of cognitive decline by 
an individual’s peers and/or family members, which are subject to biases as well. If an individual 
 49 
with developing AD either has no family members that he interacts with, or these family 
members fail to notice the signs, they may be diagnosed at a later age (Cruz et al. 2004). It is 
important to keep these factors in mind when interpreting these results.  
In addition to the association of the KCNMA1/rs16934131 SNP with AAO, it also 
revealed an association with disease duration (p=0.0002). The C allele (TC/CC genotypes) was 
associated with longer disease duration (10.97 years) than TT homozygotes (7.65 years). Since 
there were only two individuals with the CC genotype, the main contribution for longer disease 
duration was provided by the TC heterozygosity. We cannot comment on the effect of being CC 
at the KCNMA1/rs16934131 locus because disease duration information was only available for 
two individuals with this genotype.  
It is important to note that this analysis is missing vital information regarding disease 
duration. One piece of information that could aid in the interpretation of these results is cause of 
death of subjects. According to the Alzheimer’s Association, the average disease duration for 
individuals diagnosed with AD after age 60 years is 4-6 years (Alzheimer's Association  2009). 
Although AD can lead to death, AD subjects may die of various causes. However, it is necessary 
to distinguish between death with AD and death from AD. Severe dementia can cause 
complications such as difficulty with mobility, swallowing disorders, and malnutrition. These 
complications significantly increase the risk for pneumonia, which is the most frequently 
identified cause of death in individuals with AD (Alzheimer's Association  2009). Additionally, 
many elderly individuals die of causes that precipitate from one single event. For example, hip 
fracture is one of the most common injuries in the elderly. Hip injury often results from loss of 
mobility and balance, which can be features associated with AD. It is estimated that elderly 
individuals have a 5- to 8-fold increase in mortality following hip fracture (Haentjens et al. 
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2010). Therefore it is important to consider that there are causes of death, such as hip fracture, 
that may or may not be linked to AD.  
Another factor that may impact an individual’s disease duration is their quality of care 
and/or socioeconomic status, which would also help in the interpretation of these results. 
Considering AD is a debilitating disease, an individual’s quality of care may greatly impact the 
length of time that they live with AD. Without adequate care, individuals with AD may die of 
various other conditions that result from the inability to care for oneself. Socioeconomic status 
can also contribute, because an individual with AD who has the financial means to pay for an 
assisted living center and/or nursing home will likely live longer than an impoverished individual 
with AD who must care for themselves.  
Considering these factors and various others that may contribute to disease duration, it is 
possible that these data represent a confounding factor. Perhaps this SNP actually segregates 
with financial success, which leads to an individual having better access to care later in life, 
which leads to longer disease duration. Or possibly this SNP actually has an impact on an 
individual’s balance, and therefore individuals with a certain genotype have a greater propensity 
towards falling and breaking their hip which may ultimately lead to their death. Without 
additional information on cause of death and other factors it is impossible to hypothesize how 
this SNP may impact disease duration.  
The two SNPs that were found in our study to be associated with AAO and/or disease 
duration, KCNMA1/rs16934131 and ZNF224/rs3746319, were originally found to be associated 
with AD risk by Beecham et al. (2009). While our study did not find associations between these 
SNPs and AD risk, the associations seen in our study may be consistent with Beecham et al.’s 
findings. If an individual has a genetic factor that predisposes them to have a longer disease 
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duration, they are living longer with AD, and therefore there may be a greater chance that this 
individual would be chosen as a case rather than a control. Similarly, if an individual has a 
genetic factor that causes an earlier AAO, they would be affected with AD at an earlier age 
which could also increase the likelihood that they would be classified as an AD case. Therefore, 
depending on how old an individual is when they are enrolled in a study, what was seen in our 
study as a difference in disease duration or AAO, may be reflected in another study as a 
difference in case/control status.  
The KCNMA1/rs16934131 also revealed association with MMSE score in controls, in 
addition to the C10orf93/rs12781609, and PCDH11X/rs5984894 SNPs. The 
KCNMA1/rs16934131 SNP was the most statistically significant (p=0.002, n=896).  
Since MMSE score reflects cognitive impairment, it is possible that these controls 
actually do have some degree of cognitive impairment but not enough to be diagnosed with AD. 
Depending on the method of diagnosis, this difference in MMSE score could be reflected as 
difference in case-control status. It is possible that individuals with a particular genotype at this 
SNP have a greater degree of cognitive impairment and would be diagnosed as having AD when 
more stringent criteria for diagnosis is used. Therefore, potentially the same subjects that were 
classified as cases in other studies because of their cognitive impairment were classified as 
controls in our study, yet their cognitive impairment was reflected as a lower MMSE score.  
It is interesting to note that KCNMA1/rs16934131 was found to be associated with AAO, 
disease duration, and MMSE score in this study. A summary of the effects seen associated with 
KCNMA1/rs16934131 are summarized in Table 16. It is possible that this SNP does impact all 
three measures independently, or perhaps that it has one common underlying effect that is 
reflected in all three measures. It seems plausible that there could be a genetic factor that would 
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cause greater cognitive impairment, which would be represented as a lower MMSE score, 
particularly in individuals who have not had a diagnosis of AD (controls). This same effect of 
greater cognitive impairment may cause individuals to be diagnosed with AD at an earlier age, 
thus causing an overall earlier AAO. Additionally, if this genetic factor does not cause the AD to 
progress any more rapidly and these individuals would still die at a particular age, this earlier 
AAO would lead to a longer time between diagnosis and death, thus a longer disease duration.  
 
Table 16. Summary of effects associated with rs16934131 
rs16934131 
Genotype 
Means 
AAO  
(years) 
Disease 
Duration (years) 
MMSE  
score 
TT 73.06 7.65 28.52 
TC 72.93 10.97 28.32 CC 70.88 27.96 
p-value 0.045 0.0002 0.002 
 
The KCNMA1 gene has been suggested to be associated with innate immunity, cochlear 
hearing, vascular dysfunction, epilepsy, and mental retardation. Knockout mice have been 
engineered by targeted disruption of the KCNMA1 gene which showed obvious ataxia, moderate 
vascular dysfunction, and independent neurologic deficits, including cerebellar dysfunction in 
the form of abnormal eye-blink reflexes, abnormal motion, and deficiency in motor coordination 
(Sausbier et al. 2004). Considering the evidence that this gene functions in the brain and could 
potentially impact mental capacity, it seems biologically plausible that alterations in this gene 
could have an effect on an individual’s degree of cognitive impairment. Additionally, in light of 
evidence that this gene may play a role in motor coordination, it is also possible that this SNP’s 
effect on disease duration actually represents a confounding factor, such as an effect on balance, 
as previously discussed. 
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It is important to consider the implications of these findings. Although the contribution of 
these implicated SNPs to AD risk and aspects of AD may be small, these findings may help us 
more fully understand the biology behind AD, and may lead to more effective treatments in the 
future. Considering the financial impact of AD, if preventative measures could be taken in order 
to delay the onset of the disease, the financial burden on the health care system could be 
significantly lessened. When considering the large financial and social burden of AD, even small 
reductions in risks may have major public health significance.  
In summary, we did not observe statistically significant associations between the SNPs 
and the risk of AD, therefore we were unable to replicate the reported GWAS signals in our large 
case-control samples. Additionally, the candidate SNPs from chromosome 10 also showed no 
association with AD risk. Stratification by APOE*4 carrier status and stratification by sex failed 
to reveal any statistically significant associations between SNPs and AD risk. However, 
additional analysis to examine the potential associations between the examined SNPs and AAO, 
disease duration, and baseline MMSE score revealed several SNPs with statistically significant 
associations. One SNP, KCNMA1/rs16934131, was found to be associated with AAO, disease 
duration, and MMSE score.  
We must study these genes in much greater depth in order to examine these SNPs and all 
others with potential biological or positional significance. Future research may elucidate risk 
alleles for late onset AD.  
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